Mantle Cell Lymphoma

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.

A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

In patients with relapsed mantle cell lymphoma, treatment with ibrutinib might mitigate a historical trend toward decreased progression-free survival with succeeding lines of therapy.

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.

Jia Ruan, MD, PhD, hematologist/oncologist, Weil Cornell Medicine, examined the evolving treatment landscape for mantle cell lymphoma, with an emphasis on BTK inhibitors.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Andrew D. Zelenetz, MD, PhD, discusses research with zanubrutinib in mantle cell lymphoma.